Nuclear Receptors and the Control of Metabolism

Annual Review of Physiology

Volumn 65, Issue , 2003, Pages 261-311

  Francis, Gordon A ^a   Fayard, Elisabeth ^b   Picard, Frédéric ^b   Auwerx, Johan ^b  

^a CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Adipose tissue; Atherosclerosis; Cholesterol; Gene expression; Transcription

Indexed keywords

16ALPHA CYANOPREGNENOLONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BEZAFIBRATE; CELL NUCLEUS RECEPTOR; CLOFIBRATE; CYCLOSPORIN; DEXAMETHASONE; FENOFIBRATE; FURAN; GLUCOCORTICOID ANTAGONIST; HORMONE RECEPTOR STIMULATING AGENT; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; HYPOCHOLESTEROLEMIC AGENT; INDINAVIR; LINOLEIC ACID; LIVER X RECEPTOR; NC 2100; NETOGLITAZONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIFAMPICIN; SR 12813; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CELL RECEPTOR;

ADIPOCYTE; ATHEROSCLEROSIS; BILE ACID METABOLISM; CHOLESTEROL TRANSPORT; DIMERIZATION; DRUG METABOLISM; DRUG POTENCY; ENERGY METABOLISM; ENVIRONMENTAL FACTOR; EVOLUTIONARY ADAPTATION; GALLBLADDER DISEASE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEREDITY; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ABSORPTION; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; ADIPOSE TISSUE; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; ENERGY METABOLISM; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 0038210248     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.65.092101.142528     Document Type: Review

References (398)

1. Maglich JM, Sluder A, Guan X, Shi Y, McKee DD, et al. 2001. Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes. Genome Biol 2(8): RESEARCH0029
2. Robinson-Rechavi M, Carpentier AS, Duffraisse M, Laudet V. 2001. How many nuclear receptors are there in the human genome? Trends Genet. 17:554-56
3. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. 2001. Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-70
4. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, et al. 1995. The nuclear receptor superfamily: the second decade. Cell 83:835-39
5. Aranda A, Pascual A. 2001. Nuclear hormone receptors and gene expression. Physiol. Rev. 81:1269-304
6. Mangelsdorf DJ, Evans RM. 1995. The RXR heterodimers and orphan receptors. Cell 83:841-50
7. Blumberg B, Evans RM. 1998. Orphan nuclear receptors-new ligands and new possibilities. Genes Dev. 12:3149-55
8. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, et al. 1998. An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway. Cell 92:73-82
9. Willy PJ, Mangelsdorf DJ. 1996. Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. Genes Dev. 12:289-98
10. Wiebel FF, Gustafsson J-A. 1997. Heterodimeric interaction between retinoid X receptor a and orphan receptor OR-1 reveals dimerization induced activation as a novel mechanism of nuclear receptor activation. Mol. Cell Biol. 17:3977-86
11. Cavaillès V, Dauvois S, L'Horset F, Lopez G, Hoare S, et al. 1995. Nuclear factor RIP140 modulates transcriptional activation by the oestrogen receptor. EMBO J. 14:3741-51
12. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, et al. 1997. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48
13. Chen JD, Evans RM. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-57
14. Glass CK, Rosenfeld MG. 2000. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:121-41
15. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, et al. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor γ. Nature 395:137-43
16. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-57
17. Heery DM, Kalkhoven E, Hoare S, Parker MG. 1997. A signature motif in transcriptional coactivators mediates binding to nuclear receptors. Nature 387:733-36
18. Voegel JJ, Heine MJS, Zechel C, Chambon P, Gronemeyer H. 1996. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15:3667-75
19. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, et al. 1997. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677-84
20. Gelman L, Zhou G, Fajas L, Raspe E, Fruchart JC, Auwerx J. 1999. p300 interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner respectively. J. Biol. Chem. 274:7681-88
21. Zhu Y, Qi C, Calandra C, Rao MS, Reddy J. 1996. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor γ. Gene Expr. 6:185-95
22. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. 1998. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-39
23. Zhu Y, Kan L, Qi C, Kanwar YS, Yeldandi AV, et al. 2000. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J. Biol. Chem. 275:13510-16
24. Castillo G, Brun RP, Rosenfield JK, Hauser S, Park CW, et al. 1999. An adipogenic cofactor bound by the differentiation domain of PPARgamma. EMBO J. 18:3676-87
25. Heinlein CA, Ting HJ, Yeh S, Chang C. 1999. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 274:16147-52
26. Thorp JM, Waring WS. 1962. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 194:948-49
27. Hess R, Staubli W, Riess W. 1965. Nature of the hepatomegalic effect produced by ethyl chlorophenoxyisobutyrate in the rat. Nature 208:856-58
28. Isseman I, Green S. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-50
29. Graves RA, Tontonoz P, Spiegelman BM. 1992. Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression. Mol. Cell Biol. 12:1202-8
30. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W 1992. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879-87
31. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. 1992. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. 6:1634-41
32. Desvergne B, Wahli W 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20:649-88
33. Sher T, Yi HF, McBride W, Gonzalez FJ. 1993. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598-604
34. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. 1995. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and γ in the adult rat. Endocrinology 137:354-66
35. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, et al. 1997. Tissue distribution and quantification of the expression of PPARs and LXRα in humans: no alterations in adipose tissue of obese and NIDDM patients. Diabetes 46:1319-27
36. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, et al. 1998. Activation of peroxisome proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273:25573-80
37. Inoue I, Shino K, Noji S, Awata T, Katayama S. 1998. Expression of peroxisome proliferator-activated receptor alpha (PPARα) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 246:370-74
38. Staels B, Koenig W, Habib A, Merval R, Lebret M, et al. 1998. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators. Nature 393:790-93
39. Isseman I, Prince RA, Tugwood JD, Green S. 1993. The peroxisome proliferator-activated receptor: retinoic X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J. Mol. Endocrinol. 11:37-47
40. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. 1993. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA 90:2160-64
41. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, et al. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA 91:7355-59
42. Forman BM, Chen J, Evans RM. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. USA 94:4312-17
43. Gonzalez FJ, Peters JM, Cattley RC. 1998. Mechanism of action of the non-genotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J. Natl. Cancer Inst. 90:1702-9
44. Reddy JK, Lalwani ND. 1983. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit. Rev. Toxicol. 12:1-58
45. Lemberger T, Saladin R, Assimacopoulos F, Staels B, Wahli W, Auwerx J. 1996. Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. J. Biol. Chem. 271:1764-69
46. Lazennec G, Canaple L, Saugy D, Wahli W. 2000. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol. Endocrinol. 14:1962-75
47. Amri E-Z, Bonino F, Ailhaud G, Abumrad NA, Grimaldi PA. 1995. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. J. Biol. Chem. 270:2367-71
48. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, et al. 1999. Cyclooxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev. 13:1561-74
49. Krey G, Braissant O, L'Horset F, Kalkhoven E, Peroud M, et al. 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by co-activator-dependent receptor ligand assay. Mol. Endocrinol. 11:779-91
50. Moya-Camarena SY, Van den Heuvel JP, Belury MA. 1999. Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats. Biochim. Biophys. Acta 1436:331-42
51. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, et al. 1999. Novel PPARγ and PPARδ ligands produce distinct physiological effects: PPARγ activation correlates with antidiabetic activity. J. Biol. Chem. 274:6718-25
52. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, et al. 2001. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98:5306-11
53. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, et al. 2000. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell Biol. 20:5119-28
54. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, et al. 2001. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell Biol. 154:799-814
55. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, et al. 2001. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 15:3263-77
56. Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen K. 2001. Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J. Biol. Chem. 276:3175-82
57. Jow L, Mukherjee R. 1995. The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of PPARα and thyroid hormone receptors. J. Biol. Chem. 270:3836-40
58. Shi Y, Hon M, Evans RM. 2002. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl. Acad. Sci. USA 99:2613-18
59. Barak Y, Liao D, He W, Ong ES, Nelson MC, et al. 2002. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. USA 99:303-8
60. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, et al. 1997. Organization, promoter analysis and expression of the human PPARγ gene. J. Biol. Chem. 272:18779-89
61. Fajas L, Fruchart JC, Auwerx J. 1998. PPARγS mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett. 438:55-60
62. Zhu Y, Qi C, Korenberg JR, Chen X-N, Noya D, et al. 1995. Structural organization of mouse peroxisome proliferator activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc. Natl. Acad. Sci. USA 92:7921-25
63. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig A, Flier JS. 1997. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 272:20230-35
64. Ijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M. 1998. Expression of peroxisome proliferator activated receptor γ (PPARγ) in rat smooth muscle cells. Biochem. Biophys. Res. Commun. 247:353-56
65. Loviscach M, Rehman N, Carter L, Mudaliar S, Mohadeen P, et al. 2000. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 43:304-11
66. Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, et al. 2000. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 43:1165-69
67. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. 2001. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142:4195-202
68. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, et al. 1996. Regulation of PPARγ gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97:2553-61
69. Rieusset J, Andreelli D, Auboeuf D, Roques P, Valier P, et al. 1999. Insulin acutely regulates the expression of the peroxisome proliferator- activated receptor γ in human adipocytes. Diabetes 48:699-705
70. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, et al. 1997. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99:2416-22
71. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, et al. 1998. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47:98-103
72. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, et al. 1997. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA 94:4318-23
73. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 1995. 15-Deoxy-Δ12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-12
74. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, et al. 1995. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270:23975-83
75. Nagy L, Tontonez P, Alvarez JG, Chen H, Evans RM. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93:229-40
76. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:12953-56
77. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, et al. 1998. N-(2-benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. 41:5020-36
78. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, et al. 2001. A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8:737-47
79. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. 1997. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272:3406-10
80. Hu E, Kim JB, Sarraf P, Spiegelman BM. 1996. Inhibition of adipogenesis through MAP-kinase mediated phosphorylation of PPARγ. Science 274:2100-3
81. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. 1998. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339:953-59
82. Zhou Y, Gross W, Hong SH, Privalsky ML. 2001. The SMRT corepressor is a target of phosphorylation by protein kinase CK2 (casein kinase II). Mol. Cell. Biochem. 220:1-13
83. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. 1997. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272:5128-32
84. Zhang B, Berger J, Zhou G, Eibrecht A, Biswas S, et al. 1996. Insulin and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 271:31771-74
85. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. 1995. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9:1033-1045
86. Apfel R, Benbrook D, Lemhardt E, Ortiz MA, Salbert G, Pfahl M. 1994. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell Biol. 14:7025-35
87. Song C, Kokontis JM, Hiipakka RA, Liao S. 1994. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA 91:10809-13
88. Teboul M, Enmark E, Li Q, Wikström AC, Pelto-Huikko M, Gustafsson J-A. 1995. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc. Natl. Acad. Sci. USA 92:2096-100
89. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. 1996. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 383:728-31
90. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, et al. 1997. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272:3137-40
91. Song C, Hiipakka RA, Liao SS. 2000. Selective activation of liver X receptor alpha by 6 alpha-hydroxy bile acids and analogs. Steroids 65:423-27
92. Lutjohann D, Bjorkhem I, Locatelli S, Dame C, Schmolling J, et al. 2001. Cholesterol dynamics in the foetal and neonatal brain as reflected by circulatory levels of 24S-hydroxycholesterol. Acta Paediatr. 90:652-57
93. Forman BM, Ruan B, Chen J, Schroepfer GJ, Evans RM. 1997. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. USA 94:10588-93
94. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, et al. 1999. Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. Proc. Natl. Acad. Sci. USA 96:266-71
95. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, et al. 2000. Role of LXRs in control of lipogenesis. Genes Dev. 14:2831-38
96. Huang CJ, Feltkamp D, Nilsson S, Gustafsson JA. 1998. Synergistic activation of RLD-1 by agents triggering PKA and PKC dependent signaling. Biochem. Biophys. Res. Commun. 243:657-63
97. Tamura K, Chen YQE, Horiuchi M, Chen Q, Daviet L, et al. 2000. LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression. Proc. Natl. Acad. Sci. USA 97:8513-18
98. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, et al. 1995. Identification of a nuclear receptor that is activated by Farnesol metabolites. Cell 81:687-93
99. Seol W, Choi HS, Moore DD. 1995. Isolation of proteins that interact specifically with retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 9:72-85
100. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. 2000. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J. Biol. Chem. 275:10638-47
101. Zavacki AM, Lehmann JM, Seol W, Willson TM, Kliewer SA, Moore DD. 1997. Activation of the orphan receptor RIP-14 by retinoids. Proc. Natl. Acad. Sci. USA 94:7909-14
102. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. 1999. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3:543-53
103. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, et al. 1999. Identification of nuclear receptors for bile acids. Science 284:1362-65
104. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, et al. 1999. Bile acids: natural ligands for orphan nuclear receptors. Science 284:1365-68
105. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, et al. 1998. Identification of a human nuclear receptor defines a new signaling pathway for CYP3 A induction. Proc. Natl. Acad. Sci. USA 95:12208-13
106. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, et al. 1998. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12:3195-205
107. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, et al. 2000. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14:27-39
108. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. 1998. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102:1016-23
109. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, et al. 2001. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-72
110. Schuetz EG, Brimer C, Schuetz JD. 1998. Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol. Pharmacol. 54:1113-17
111. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, et al. 2001. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA 98:3369-74
112. Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, et al. 2001. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. USA 98:3375-80
113. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, et al. 2001. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 276:39411-18
114. Moore JT, Kliewer SA. 2000. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153:1-10
115. Selye H. 1971. Hormones and resistance. J. Pharm. Sci. 60:1-28
116. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, et al. 2000. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-39
117. Ikeda Y, Lala SD, Luo X, Kim E, Moisan MP, Parker KL. 1993. Characterization of the mouse FTZ-F1 gene, which encodes a key regulator of steroid hydroxylase gene expression. Mol. Endocrinol. 7:852-60
118. Lavorgna G, Ueda H, Clos J, Wu C. 1991. FTZ-F1, a steroid hormone receptor-like protein implicated in the activation of fushi tarazu. Science 252:848-51
119. Lavorgna G, Karim FD, Thummel CS, Wu C. 1993. Potential role for a FTZ-F1 steroid receptor superfamily member in the control of Drosophila metamorphosis. Proc. Natl. Acad. Sci. USA 90:3004-8
120. Kudo T, Sutou S. 1997. Molecular cloning of chicken FTZ-F1-related orphan receptors. Gene 2197:261-68
121. Chai C, Chan W. 2000. Developmental expression of a novel ftz-F1 homologue, ff1b (NR5A4), in the zebrafish Danio rerio. Mech. Dev. 91:421-26
122. Galarneau L, Drouin R, Bèlanger L. 1998. Assignment of the fetoprotein transcription factor gene (FTF) to human chromosome band 1q32.11 by in situ hybridization. Cytogenet. Cell Genet. 82:269-70
123. Li M, Xie Y-H, Kong Y-Y, Wu X, Zhu L, Wang Y. 1998. Cloning and characterization of a novel human hepatocyte transcription factor, hB1F, which binds and activates enhancer II of hepatitis B virus. J. Biol. Chem. 273:29022-31
124. Nitta M, Ku S, Brown C, Okamoto AY, Shan B. 1999. CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene. Proc. Natl. Acad. Sci. USA 96:6660-65
125. Lu TT, Repa JJ, Mangelsdorf DJ. 2001. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J. Biol. Chem. 276:37735-38
126. del Castillo-Olivares A, Gil G. 2000. Alpha 1-fetoprotein transcription factor is required for the expression of sterol 12alpha-hydroxylase, the specific enzyme for cholic acid synthesis. Potential role in the bile acid-mediated regulation of gene transcription. J. Biol. Chem. 275:17793-99
127. del Castillo-Olivares A, Gil G. 2000. Role of FXR and FTF in bile acid-mediated suppression of cholesterol 7alpha-hydroxylase transcription. Nucleic Acids Res. 28:3587-93
128. 1-fetoprotein locus is activated by a nuclear receptor of the Drosphila Ftz-F1 family. Mol. Cell Biol. 16:3853-65
129. Lee YK, Parker KL, Choi HS, Moore DD. 1999. Activation of the promoter of the orphan receptor SHP by orphan receptors that bind DNA as monomers. J. Biol. Chem. 274:20869-73
130. Luo Y, Liang CP, Tall AR. 2001. The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor. J. Biol. Chem. 276:24767-73
131. Inokuchi A, Hinoshita E, Iwamoto Y, Kohno K, Kuwano M, Uchiumi T. 2001. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J. Biol. Chem. 276:46822-29
132. Clyne CD, Speed CJ, Zhou J, Simpson ER. 2002. Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J. Biol. Chem. 277:20591-97
133. Wang ZN, Bassett M, Rainey WE. 2001. Liver receptor homologue-1 is expressed in the adrenal and can regulate transcription of 11 beta-hydroxylase. J. Mol. Endocrinol. 27:255-58
134. Takase M, Nakajima T, Nakamura M. 2000. FTZ-F1alpha is expressed in the developing gonad of frogs. Biochim. Biophys. Acta 1494:195-200
135. Rausa FM, Galarneau L, Bélanger L, Costa RH. 1999. The nuclear receptor fetoprotein transcription factor is co-expressed with its target gene HNF-3β in the developing murine liver, intestine and pancreas. Mech. Dev. 89:185-88
136. Seol W, Choi HS, Moore DD. 1996. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 212:1336-39
137. Lee HK, Lee YK, Park SH, Kim YS, Lee JW, et al. 1998. Structure and expression of the orphan nuclear receptor SHP gene. J. Biol. Chem. 273:14398-402
138. Masuda N, Yasumo H, Tamura T, Hashiguchi N, Furusawa T, et al. 1997. An orphan nuclear receptor lacking a zinc-finger DNA-binding domain: interaction with several nuclear receptors. Biochim. Biophys. Acta 1350:27-32
139. Johansson L, Thomsen JS, Damdimopoulos AE, Spyrou G, Gustafsson JA, Treuter E. 1999. The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogenreceptors ER alpha and ER beta. J. Biol. Chem. 274:345-53
140. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, et al. 2000. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6:517-26
141. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, et al. 2000. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6:507-15
142. Lee YK, Moore DD. 2002. Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner. J. Biol. Chem. 277:2463-67
143. Brendel C, Schoonjans K, Treuter E, Auwerx J. 2002. The small heterodimer partner (SHP) interacts with the liver X receptor alpha (LXRalpha) and represses its transcriptional activity. Mol. Endocrinol. 16:2065-76
144. Lee YK, Dell H, Dowhan DH, Hadzopoulou-Cladaras M, Moore DD. 2000. The orphan nuclear receptor SHP inhibits hepatocyte nuclear factor 4 and retinoid X receptor transactivation: two mechanisms for repression. Mol. Cell Biol. 20:187-95
145. Seol W, Chung M, Moore DD. 1997. Novel receptor interaction and repression domains in the orphan receptor SHP. Mol. Cell Biol. 17:7126-31
146. Nishizawa H, Yamagata K, Shimomura I, Takahashi M, Kuriyama H, et al. 2002. Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor gamma transactivation. J. Biol. Chem. 277:1586-92
147. Kassam A, Capone JP, Rachubinski RA. 2001. The short heterodimer partner receptor differentially modulates peroxisome proliferator-activated receptor alpha-mediated transcription from the peroxisome proliferator-response elements of the genes encoding the peroxisomal beta-oxidation enzymes acyl-CoA oxidase and hydratase-dehydrogenase. Mol. Cell. Endocrinol. 176:49-56
148. Nishigori H, Tomura H, Tonooka N, Kanamori M, Yamada S, et al. 2001. Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects. Proc. Natl. Acad. Sci. USA 98:575-80
149. Tontonoz P, Hu E, Spiegelman BM. 1994. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79:1147-56
150. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. 1994. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1224-34
151. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman R, Briggs M, et al. 1996. PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:5336-48
152. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, et al. 1995. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 270:19269-76
153. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. 1995. PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell Biol. 15:351-57
154. Bakopanos E, Silva JE. 2000. Thiazolidinediones inhibit the expression of beta3-adrenergic receptors at a transcriptional level. Diabetes 49:2108-15
155. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, et al. 1996. Thiazolidinediones repress ob gene expression via activation of PPARγ. J. Clin. Invest. 98:1004-9
156. Kallen CB, Lazar MA. 1996. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. USA 93:5793-96
157. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, et al. 1994. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 134:264-70
158. Szalkowski D, White-Carrington S, Berger J, Zhang B. 1995. Antidiabetic thiazolidinediones block the inhibitory effects of TNFα on differentiation, insulin stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136:1474-81
159. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. 2000. Transcriptional regulation of adipogenesis. Genes Dev. 14:1293-1307
160. Morrison RF, Farmer SR. 2000. Hormonal signaling and transcriptional control of adipocyte differentiation. J. Nutr. 130:83116-21
161. Fajas L, Debril MB, Auwerx J. 2001. PPAR gamma: an essential role in metabolic control. Nutr. Metab. Cardiovasc. Dis. 11:64-69
162. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. 2000. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105:287-92
163. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, et al. 1999. PPARg mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4:597-609
164. Deeb S, Fajas L, Nemoto M, Laakso M, Fujimoto W, Auwerx J. 1998. A Pro
165. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, et al. 1997. Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians: identification of a Pro12Ala PPARgamma 2 missense mutation. Biochem. Biophys. Res. Commun. 241:270-74
166. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, et al. 2000. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26:76-80
167. Kelly IE, Han TS, Walsh K, Lean ME. 1999. Effects of athiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-93
168. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, et al. 2001. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-19
169. Burkey BF, Dong M, Gagen K, Eckhardt M, Dragonas N, et al. 2000. Effects of pioglitazone on promoting energy storage, not expenditure, in brown adipose tissue of obese fa/fa Zucker rats: comparison to CL 316, 243. Metabolism 49:1301-8
170. Wang Q, Bing C, Al-Barzanji K, Mossakowaska DE, Wang XM, et al. 1997. Interactions between leptin and hypothalamic neuropeptide Y neurons in the control of food intake and energy homeostasis in the rat. Diabetes 46:335-41
171. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, et al. 1999. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102-7
172. Mon Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, et al. 1999. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-12
173. Okuno A, Tamemoto H, Tobe K, Ueki K, Mon Y, et al. 1998. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101:1354-61
174. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, et al. 1997. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/ fa rat. Diabetes 46:1393-99
175. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, et al. 2001. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50:1863-71
176. Fukui Y, Masui S, Osada S, Umesono K, Motojima K. 2000. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 49:759-67
177. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, et al. 1998. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor y-activating properties. J. Biol. Chem. 273:32679-84
178. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, et al. 1999. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. USA 96:6102-6
179. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, et al. 2000. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. 275:1873-77
180. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, et al. 2000. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol. Endocrinol. 14:1425-33
181. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, et al. 2001. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J. Clin. Invest. 108:1001-13
182. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, et al. 1998. Life without fat: a transgenic mouse. Genes Dev. 12:3168-81
183. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, et al. 1998. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: a model for congenital generalized lipodystrophy. Genes Dev. 12:3182-94
184. Garg A, Peshock RM, Fleckenstein JL. 1999. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J. Clin. Endocrinol. Metab. 84:170-74
185. Mauriege P, Imbeault P, Langin D, Lacaille M, Almeras N, et al. 1999. Regional and gender variations in adipose tissue lipolysis in response to weight loss. J. Lipid Res. 40:1559-71
186. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, et al. 2001. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-77
187. Auwerx J. 1999. PPARγ, the ultimate thrifty gene. Diabetologia 42:1033-49
188. Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, et al. 2001. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Mol. Pharmacol. 59:170-76
189. Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, et al. 2001. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol. Pharmacol. 59:765-73
190. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW 2001. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50:411-17
191. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW 1994. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-10
192. Wu M, Ventre J, Moller DE, Doebber T. 1997. Correction of elevated glucose and triglycerides in Zucker diabetic fatty rats by thiazolidinediones parallels increased I-glycogen synthase and lipoprotein lipase activity in muscle and fat. Diabetes 46(Suppl. 1):A237
193. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW 1997. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue availability in the rat. Metabolism 46:935-42
194. Martin G, Schoonjans K, Lefebvre A, Staels B, Auwerx J. 1997. Coordinate regulation of the expression of the fatty acid transport protein (FATP) and acyl CoA synthetase genes by PPARα and PPARγ activators. J. Biol. Chem. 272:28210-17
195. Schoonjans K, Martin G, Staels B, Auwerx J. 1997. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8:159-66
196. Martin G, Schoonjans K, Staels B, Auwerx J. 1998. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 137:75-80
197. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose tissue expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91
198. Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, et al. 1997. Targeted disruption of the tumor necrosis factor-α gene: metabolic consequences in obese and non-obese mice. Diabetes 46:1526-31
199. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-14
200. Schreyer SA, Chua SC Jr, LeBoeuf RC. 1998. Obesity and diabetes in TNF-alpha receptor-deficient mice. J. Clin. Invest. 102:402-11
201. Cohen B, Novick D, Rubinstein M. 1996. Modulation of insulin activities by leptin. Science 274:1185-88
202. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, et al. 2001. The hormone resistin links obesity to diabetes. Nature 409:307-12
203. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, et al. 2001. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 276:25651-53
204. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, et al. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543-46
205. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. 1997. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389:374-77
206. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al. 2001. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab. 86:3815-19
207. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257:79-83
208. Vionnet N, Hani E, Dupont S, Gallina S, Francke S, et al. 2000. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am. J. Hum. Genet. 67:1470-80
209. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, et al. 2000. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl. Acad. Sci. USA 97:14478-83
210. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86:1930-35
211. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, et al. 2001. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-33
212. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, et al. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7:941-46
213. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7:947-53
214. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, et al. 2001. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099
215. Iwata M, Haruta T, Usui I, Takata Y, Takano A, et al. 2001. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator- activated receptor-gamma. Diabetes 50:1083-92
216. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. 2001. Thiazolidinediones (PPAR gamma agonists) but not PPAR alpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J. 15:215-20
217. Rieusset J, Auwerx J, Vidal H. 1999. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem. Biophys. Res. Commun. 265:265-71
218. Ribon V, Johnson JH, Camp HS, Saltiel AR. 1998. Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proc. Natl. Acad. Sci. USA 95:14751-56
219. Baumann CA, Chokshi N, Saltiel AR, Ribon V. 2000. Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene. J. Biol. Chem. 275:9131-35
220. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. 1990. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-62
221. Zhang B, Szalkowski D, Diaz E, Hayes N, Smith R, Berger J. 1994. Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptor and L6 myotubes. J. Biol. Chem. 269:25735-41
222. Kausch C, Krutzfeldt J, Witke A, Rettig A, Bachmann O, et al. 2001. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem. Biophys. Res. Commun. 280:664-74
223. Cha BS, Ciaraldi TP, Carter L, Nikoulina SE, Mudaliar S, et al. 2001. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 44:444-52
224. Majer M, Popov KM, Harris RA, Bogardus C, Prochazka M. 1998. Insulin downregulates pyruvate dehydrogenase kinase (PDK) mRNA: potential mechanism contributing to increased lipid oxidation in insulin-resistant subjects. Mol. Genet. Metab. 65:181-86
225. Yonemitsu S, Nishimura H, Shintani M, Inoue R, Yamamoto Y, et al. 2001. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 50:1093-1101
226. Arakawa K, Ishihara T, Aoto M, Inamasu M, Saito A, Ikezawa K. 1998. Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells. Br. J. Pharmacol. 125:429-36
227. Cnop M, Hannaert JC, Pipeleers DG. 2002. Troglitazone does not protect rat pancreatic beta cells against free fatty acid-induced cytotoxicity. Biochem. Pharmacol. 63:1281-85
228. Shimabukuro M, Zhou YT, Lee Y, Unger RH. 1998. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem. 273:3547-50
229. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. 1999. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc. Natl. Acad. Sci. USA 96:11513-18
230. Ogawa J, Takahashi S, Fujiwara T, Fukushige J, Hosokawa T, et al. 1999. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci. 65:1287-96
231. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, et al. 2001. β-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-29
232. Kawai T, Hirose H, Seto Y, Fujita H, Ukeda K, Saruta T. 2002. Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma. Diabetes Res. Clin. Pract. 56:83-92
233. Jia DM, Otsuki M. 2002. Troglitazone stimulates pancreatic growth in normal rats. Pancreas 24:303-12
234. Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, Ahn YH. 2000. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 49:1517-24
235. Kim HI, Cha JY, Kim SY, Kim JW, Roh KJ, et al. 2002. Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes 51:676-85
236. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. 1997. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J. Clin. Invest. 100:530-37
237. Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, et al. 1996. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes 45:1572-79
238. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, et al. 1998. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. N. Engl. J. Med. 338:867-72
239. Suter SL, Nolan J, Wallace P, Gumbiner B, Olefsky JM. 1992. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203
240. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, et al. 1998. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 128:176-85
241. Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, et al. 1997. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin. Pharmacol. Ther. 62:194-202
242. Reddy JK, Hashimoto T. 2001. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21:193-230
243. Schoonjans K, Staels B, Auwerx J. 1996. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37:907-25
244. Barger PM, Kelly DP. 2000. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10:238-45
245. Schoonjans K, Staels B, Auwerx J. 1996. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302:93-109
246. Staels B, Vu-Dac N, Kosykh V, Saladin R, Fruchart JC, et al. 1995. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl co-enzyme A oxidase. J. Clin. Invest. 95:705-12
247. Haubenwallner S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, et al. 1995. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J. Lipid Res. 36:2541-51
248. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. 1985. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75:384-90
249. Shachter NS. 2001. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12:297-304
250. Hsu MH, Savas U, Griffin KJ, Johnson EF. 2001. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J. Biol. Chem. 276:27950-58
251. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, et al. 2001. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. J. Biol. Chem. 276:31521-27
252. Lapsys NM, Kriketos AD, Lim-Fraser M, Poynten AM, Lowy A, et al. 2000. Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle. J. Clin. Endocrinol. Metab. 85:4293-97
253. Michaud SE, Renier G. 2001. Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs. Diabetes 50:660-66
254. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, et al. 2002. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell Biol. 22:2607-19
255. Carroll R, Severson DL. 2001. Peroxisome proliferator-activated receptor-alpha ligands inhibit cardiac lipoprotein lipase activity. Am. J. Physiol. Heart Circ. Physiol. 281:H888-H94
256. Zhang Y, Repa JJ, Gauthier K, Mangelsdorf DJ. 2001. Regulation of lipoprotein lipase by the oxysterol receptors, LXR alpha and LXR beta. J. Biol. Chem. 276:43018-24
257. Rubins HB, Robins SJ, Iwane MK, Boden WE, Elam MB, et al. 1993. Rationale and design of the Department of Veterans Affairs High Density Lipoprotein Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high density lipoprotein cholesterol and desirable low density lipoprotein cholesterol. Am. J. Cardiol. 71:45-52
258. Francis GA, Perry RJ. 1999. Targeting HDL-mediated cellular cholesterol efflux for the treatment and prevention of atherosclerosis. Clin. Chim. Acta 286:219-30
259. Fielding CJ, Fielding PE. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:211-28
260. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353:265-67
261. Plump AS, Scott CJ, Breslow JL. 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA 91:9607-11
262. Paszty C, Maeda N, Verstuyft J, Rubin EM. 1994. Apolipoprotein AI transgene mice corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94:899-903
263. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, et al. 1996. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein AI-transgenic rabbits. Circulation 94:713-17
264. Eriksson M, Carlson LA, Miettinen TA, Angelin B. 1999. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans. Circulation 1000:594-98
265. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B. 1994. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J. Biol. Chem. 269:31012-18
266. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart J-C, et al. 1995. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest. 96:741-50
267. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Heyman RA, et al. 1996. Retinoids increase human apolipoprotein A-II expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol. Cell Biol. 16:3350-60
268. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, et al. 1998. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erb alpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem. 273:25713-20
269. Hennuyer N, Poulain P, Madsen L, Berge RK, Houdebine LM, et al. 1999. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation 99:2445-51
270. Havel RJ, Kane JP. 1995. Structure and metabolism of plasma lipoproteins. In The Metabolic and Molecular Bases of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, pp. 1841-52. New York: McGraw-Hill
271. Bruce C, Chouinard RA Jr, Tall AR. 1998. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu. Rev. Nutr. 18:297-330
272. Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, et al. 1998. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J. Lipid Res. 39:17-30
273. Oram JF, Yokoyama S. 1996. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J. Lipid Res. 37:2473-91
274. Makrides SC, Ruiz-Opazo N, Hayden M, Nussbaum AL, Breslow JL, Zannis VI. 1988. Sequence and expression of Tangier apoA-I gene. Eur. J. Biochem. 173:465-71
275. Kay LL, Ronan R, Schaefer EJ, Brewer HB Jr. 1982. Tangier disease: a structural defect in apolipoprotein A-I (apoA-I Tangier). Proc. Natl. Acad. Sci. USA 79:2485-89
276. Francis GA, Knopp RH, Oram JF. 1995. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J. Clin. Invest. 96:78-87
277. Remaley AT, Schumacher UK, Stonik JA, Farsi BD, Nazih H, Brewer HB Jr. 1997. Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler. Thromb. Vasc. Biol. 17:1813-21
278. Phillips MC, Gillotte KL, Haynes MP, Johnson WJ, Lund-Katz S, Rothblat GH. 1998. Mechanisms of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes. Atherosclerosis 137(Suppl.):S13-17
279. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, et al. 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:336-45
280. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, et al. 1999. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:347-51
281. Rust S, Rosier M, Funke H, Real J, Amoura Z, et al. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:352-55
282. Lawn RM, Wade DP, Garvin MR, Wang X, Schwanz K, et al. 1999. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 104:R25-31
283. Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, et al. 1999. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 354:1341-46
284. Brousseau ME, Eberhart GP, Dupuis J, Asztalos BF, Goldkamp AL, et al. 2000. Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J. Lipid Res. 41:1125-35
285. Neufeld EB, Remaley AT, Demosky SJ, Stonik JA, Cooney AM, et al. 2001. Cellular localization and trafficking of the human ABCA1 transporter. J. Biol. Chem. 276:27584-90
286. Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, et al. 2000. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice. Nat. Genet. 24:192-96
287. Hamon Y, Broccardo C, Chambenoit O, Luciani MF, Toti F, et al. 2000. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat. Cell Biol. 2:399-406
288. Fielding PE, Nagao K, Hakamata H, Chimini G, Fielding CJ. 2000. A two-step mechanism for free cholesterol and phospholipid efflux from human vascular cells to apolipoprotein A-1. Biochemistry 39:14113-20
289. Wang N, Silver DL, Thiele C, Tall AR. 2001. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J. Biol. Chem. 276:23742-47
290. Mendez AJ, Lin G, Wade DP, Lawn RM, Oram JF. 2001. Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway. J. Biol. Chem. 276:3158-66
291. Oram JF, Lawn RM. 2001. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. 42:1173-79
292. Chen W, Silver DL, Smith JD, Tall AR. 2000. Scavenger receptor-BI inhibits ATP-binding cassette transporter 1-mediated cholesterol efflux in macrophages. J. Biol. Chem. 275:30794-800
293. Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, et al. 1999. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem. Biophys. Res. Commun. 257:29-33
294. Lawn RM, Wade DP, Couse TL, Wilcox JN. 2001. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler. Thromb. Vasc. Biol. 21:378-85
295. Liao H, Langmann T, Schmitz G, Zhu Y. 2002. Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22:127-32
296. Schwanz K, Lawn R, Wade DP. 2000. ABC1 gene expression and apoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274:794-802
297. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. 1998. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 273:29577-85
298. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, et al. 2000. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289:1524-29
299. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, et al. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA 97:12097-102
300. Costet P, Luo Y, Wang N, Tall AR. 2000. Sterol-dependent transactivation of the human ABC1 promoter by liver X receptor/retinoid X receptor. J. Biol. Chem. 275:28240-45
301. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, et al. 2001. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. USA 98:2610-15
302. Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, et al. 2000. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha. Mol. Endocrinol. 14:741-52
303. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7:53-58
304. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7:161-71
305. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99:7604-9
306. 305a. Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, et al. 2002. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA 99:11896-901
307. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, et al. 2001. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 7:41-47
308. Sparrow CP, Baffic J, Lam MH, Lund EG, Adams AD, et al. 2002. A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J. Biol. Chem. 277:10021-27
309. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, et al. 2002. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277:11019-25
310. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, et al. 2000. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXR-beta. Genes Dev. 14:2819-30
311. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. 2002. Diminished hepatic response to fasting/ refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J. Biol. Chem. 277:9520-28
312. Joseph SB, McKilligin E, Pei LM, Watson MA, Collins AR, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99:7604-9
313. Joyce CW, Amar MJ, Lambert G, Vaisman BL, Paigen B, et al. 2002. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Natl. Acad. Sci. USA 99:407-12
314. Oram JF, Lawn RM, Garvin MR, Wade DP. 2000. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J. Biol. Chem. 275:34508-11
315. Takahashi Y, Miyata M, Zheng P, Imazato T, Horwitz A, Smith JD. 2000. Identification of cAMP analogue inducible genes in RAW264 macrophages. Biochim. Biophys. Acta 1492:385-94
316. Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, et al. 2000. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc. Natl. Acad. Sci. USA 97:817-22
317. Venkateswaran A, Repa JJ, Lobaccaro J-MA, Bronson A, Mangelsdorf DJ. 2000. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. J. Biol. Chem. 275:14700-7
318. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, et al. 2001. LXRs control lipid-inducible expression of the apolipoprotein E.gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. USA 98:507-12
319. Mak PA, Laffitte BA, Desrumaux C, Joseph SB, Curtiss LK, et al. 2002. Regulated expression of the ApoE/C-I/C-IV/C-II gene cluster in murine and human macrophages; a critical role for the nuclear receptors LXRalpha and LXR-beta. J. Biol. Chem. 277:31900-8
320. Kohro T, Nakajima T, Wada Y, Sugiyama A, Ishii M, et al. 2000. Genomic structure and mapping of human orphan receptor LXR alpha: upregulation of LXRa mRNA during monocyte to macrophage differentiation. J. Atheroscler. Thromb. 7:145-51
321. Whitney KD, Watson MA, Goodwin B, Galardi CM, Maglich JM, et al. 2001. Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J. Biol. Chem. 276:43509-15
322. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, et al. 2001. Autoregulation of the human liver X receptor alpha promoter. Mol. Cell Biol. 21:7558-68
323. Li Y, Bolten C, Bhat BG, Woodring-Dietz J, Li S, et al. 2002. Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism. Mol. Endocrinol. 16:506-14
324. Wang N, Silver DL, Costet P, Tall AR. 2000. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J. Biol. Chem. 275:33053-58
325. Rothblatt GH, Mahlberg FH, Johnson WJ, Phillips MC. 1992. Apolipoprotein, membrane cholesterol domains and the regulation of cholesterol efflux. J. Lipid Res. 33:1091-1097
326. Urizar NL, Dowhan DH, Moore DD. 2000. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J. Biol. Chem. 275:39313-17
327. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, et al. 2001. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J. Biol. Chem. 276:25841-47
328. Tall A. 1993. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34:1255-74
329. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. 1992. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J. Clin. Invest. 90:1290-95
330. Luo Y, Tall AR. 2000. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105:513-20
331. Radeau T, Lau P, Robb M, McDonnell M, Ailhaud G, McPherson R. 1995. Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. J. Lipid Res. 36:2552-61
332. Staels B, Peinado-Onsurbe J, Auwerx J. 1992. Down-regulation of hepatic lipase gene expression and activity by fenofibrate. Biochim. Biophys. Acta 1123:227-30
333. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, et al. 2000. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101:2411-17
334. Andersson S, Davis DL, Dahlback H, Jornvall H, Russell DW. 1989. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem. 264:8222-29
335. Cali JJ, Russell DW. 1991. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J. Biol. Chem. 266:7774-78
336. Babiker A, Andersson O, Lindblom D, van der Linden J, Wiklund B, et al. 1999. Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase: evidence that most of this steroid in the circulation is of pulmonary origin. J. Lipid Res. 40:1417-25
337. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, et al. 2001. 27-hydroxy-cholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276:38378-87
338. Song C, Liao S. 2000. Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 141:4180-84
339. Oftebro H, Bjorkhem I, Skrede S, Schreiner A, Pederson JI. 1980. Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid. J. Clin. Invest. 65:1418-30
340. Cali JJ, Hsieh CL, Francke U, Russell DW. 1991. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J. Biol. Chem. 266:7779-83
341. Repa JJ, Lund EG, Horton JD, Leitersdorf E, Russell DW, et al. 2000. Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J. Biol. Chem. 275:39685-92
342. Van Erpecum KJ, Portincasa P, Gadellaa M, Van de Heijning BJ, Van Berge Henegouwen GP, Renooij W 1996. Effects of bile salt hydrophobicity on crystallization of cholesterol in model bile. Eur. J. Clin. Invest. 26:602-8
343. Fayard E, Schoonjans K, Auwerx J. 2001. Xol INXS: role of the liver X and the farnesol X receptors. Curr. Opin. Lipidol. 12:113-20
344. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, et al. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93:693-704
345. 343a. Chiang JY, Kimmel R, Stroup D. 2001. Regulation of cholesterol 7 alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXR-alpha). Gene 262:257-65
346. Agellon LB, Drover VAB, Cheema SK, Gbaguidi GF, Walsh A. 2002. Dietary cholesterol fails to stimulate the human cholesterol 7alpha-hydroxylase gene (CYP7A1) in transgenic mice. J. Biol. Chem. 277:20131-34
347. Sinai CJ, Tonkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. 2000. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731-44
348. Chen W, Owsley E, Yang Y, Stroup D, Chiang JY. 2001. Nuclear receptor-mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids. J. Lipid Res. 42:1402-12
349. del Castillo-Olivares A, Gil G. 2001. Suppression of sterol 12alpha-hydroxylase transcription by the short heterodimer partner: insights into the repression mechanism. Nucleic Acids Res. 29:4035-42
350. Zhang M, Chiang JY. 2001. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression. J. Biol. Chem. 276:41690-99
351. Pare JF, Roy S, Galarneau L, Belanger L. 2001. The mouse fetoprotein transcription factor (ftf) gene promoter is regulated by three gata elements with tandem e box and nkx motifs, and ftf in turn activates the hnf3beta, hnf4alpha, and hnf1alpha gene promoters. J. Biol. Chem. 276:13136-44
352. Stroup D, Crestani M, Chiang JY. 1997. Identification of a bile acid response element in the cholesterol 7 alpha-hydroxylase gene CYP7A. Am. J. Physiol. Gastrointest. Liver Physiol. 273:G508-G17
353. Cooper AD, Chen J, Botelho-Yetkinler MJ, Cao Y, Taniguchi T, Levy-Wilson B. 1997. Characterization of hepatic-specific regulatory elements in the promoter region of the human cholesterol 7alpha-hydroxylase gene. J. Biol. Chem. 272:3444-52
354. Grober J, Zaghini I, Fujii H, Jones SA, Kliewer SA, et al. 1999. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis- retinoic acid receptor heterodimer. J. Biol. Chem. 274:29749-54
355. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, et al. 1998. Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am. J. Physiol. Gastrointest. Liver Physiol. 274:G370-G75
356. Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, et al. 2001. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121:140-47
357. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. 2001. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276:28857-65
358. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, et al. 2000. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290:1771-75
359. Nebert DW. 1991. Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. Mol. Endocrinol. 5:1203-14
360. Xie W, Evans RM. 2002. Pharmaceutical use of mouse models humanized for the xenobiotic receptor. Drug Discov. Today 7:509-15
361. Denison MS, Whitlock JP Jr. 1995. Xenobiotic-inducible transcription of cytochrome P450 genes. J. Biol. Chem. 270:18175-78
362. Gonzalez FJ. 1992. Human cytochromes P450: problems and prospects. Trends Pharmacol. Sci. 13:346-52
363. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. 2001. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 59:386-92
364. Gonzalez FJ, Liu SY, Yano M. 1993. Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenetics 3:51-57
365. Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P, Vilarem MJ. 2001. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab. Dispos. 29:1325-31
366. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, et al. 2001. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. 29:242-51
367. Synold TW, Dussault I, Forman BM. 2001. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7:584-90
368. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. 2001. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 60:427-31
369. Ekins S, Wrighton SA. 1999. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31:719-54
370. Falkner KC, Pinaire JA, Xiao GH, Geoghegan TE, Prough RA. 2001. Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol. Pharmacol. 60:611-19
371. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, et al. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:147-53
372. Geick A, Eichelbaum M, Burk O. 2001. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276:14581-87
373. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. 2001. Peptide mimetic HTV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 276:33309-12
374. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, et al. 2002. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277:2908-15
375. Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, et al. 1996. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271:15091-98
376. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, et al. 1998. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101:1310-19
377. Kawabe T, Chen ZS, Wada M, Uchiumi T, Ono M, et al. 1999. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. 456:327-31
378. Paulusma CC, Oude Elferink RP. 1997. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J. Mol. Med. 75:420-28
379. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, et al. 1996. Congenital jaundice in rats with a mutation in a multidrug resistance- associated protein gene. Science 271:1126-28
380. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM. 2001. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol. Lett. 120:51-57
381. Noe B, Hagenbuch B, Stieger B, Meier PJ. 1997. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. USA 94:10346-50
382. Reichel C, Gao B, Van Montfoort J, Cattori V, Rahner C, et al. 1999. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology 117:688-95
383. Suzuki H, Sugiyama Y. 2000. Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. Semin. Liver Dis. 20:251-63
384. Guo GL, Staudinger J, Ogura K, Klaassen CD. 2002. Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. Mol. Pharmacol. 61:832-39
385. Ernst E, Rand JI, Barnes J, Stevinson C. 1998. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur. J. Clin. Pharmacol. 54:589-94
386. Ernst E. 1999. Second thoughts about safety of St John's wort. Lancet 354:2014-16
387. Fugh-Berman A. 2000. Herb-drug interactions. Lancet 355:134-38
388. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations and St John's wort. Lancet 355:547-48
389. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. 2000. Acute heart transplant rejection due to Saint John's wort. Lancet 355:548-49
390. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, et al. 2000. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA 97:7500-2
391. Honkakoski P, Zelko I, Sueyoshi T, Negishi M. 1998. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital- responsive enhancer module of the CYP2B gene. Mol. Cell Biol. 18:5652-58
392. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, Negishi M. 1999. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol. Cell Biol. 19:6318-22
393. Choi HS, Chung M, Tzameli I, Simha D, Lee YK, et al. 1997. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J. Biol. Chem. 272:23565-71
394. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. 1999. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem. 274:6043-46
395. Xie W, Barwick JL, Simon CM, Pierce AM, Safe S, et al. 2000. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 14:3014-23
396. Smirlis D, Muangmoonchai R, Edwards M, Phillips IR, Shephard EA. 2001. Orphan receptor promiscuity in the induction of cytochromes p450 by xenobiotics. J. Biol. Chem. 276:12822-26
397. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, et al. 2000. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275:15122-27
398. Xie W, Evans RM. 2001. Orphan nuclear receptors: the exotics of xenobiotics. J. Biol. Chem. 276:37739-42